EDITORIAL
The end of “very low risk” in localized prostate cancer?
Federico Ferraris MD,
Fabian Yaber MD, PhD,
Angela B. Smith MD, MS, FACS,
Diego Barreiro MD,
Corresponding Author
Federico Ferraris MD
Sanatorio Dupuytren, CABA, Buenos Aires, Argentina
Correspondence Federico Ferraris, MD, Sanatorio Dupuytren, CABA, Buenos Aires CP1210, Argentina.
Email: [email protected]
Search for more papers by this authorFabian Yaber MD, PhD
National University of Rosario and Sanatorio de la Mujer, Santa Fe, Argentina
Search for more papers by this authorAngela B. Smith MD, MS, FACS
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA
Search for more papers by this authorDiego Barreiro MD
Instituto de Investigaciones Médicas Dr. Alfredo Lanari, University of Buenos Aires, Buenos Aires, Argentina
Search for more papers by this authorFederico Ferraris MD,
Fabian Yaber MD, PhD,
Angela B. Smith MD, MS, FACS,
Diego Barreiro MD,
Corresponding Author
Federico Ferraris MD
Sanatorio Dupuytren, CABA, Buenos Aires, Argentina
Correspondence Federico Ferraris, MD, Sanatorio Dupuytren, CABA, Buenos Aires CP1210, Argentina.
Email: [email protected]
Search for more papers by this authorFabian Yaber MD, PhD
National University of Rosario and Sanatorio de la Mujer, Santa Fe, Argentina
Search for more papers by this authorAngela B. Smith MD, MS, FACS
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA
Search for more papers by this authorDiego Barreiro MD
Instituto de Investigaciones Médicas Dr. Alfredo Lanari, University of Buenos Aires, Buenos Aires, Argentina
Search for more papers by this authorNo abstract is available for this article.
CONFLICT OF INTERESTS
Astellas speaker and advisor, Bayer speaker and advisor.
REFERENCES
- 1Mohler JL. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. J Natl Compr Canc Netw. 2010; 8(2): 145. https://doi.org/10.6004/jnccn.2010.0010
- 2Sanda MG, Cadeddu JA, Kirkby E, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options. J Urol. 2018; 199(3): 683-690. https://doi.org/10.1016/j.juro.2017.11.095
- 3Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994; 271(5): 368-374.
- 4Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016; 40(2): 244-252. https://doi.org/10.1097/PAS.0000000000000530
- 5Karram S, Trock BJ, Netto GJ, Epstein JI. Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings. Am J Surg Pathol. 2011; 35(9): 1351-1355. https://doi.org/10.1097/PAS.0b013e3182217b79
- 6van Leenders GJLH, van der Kwast TH, Grignon DJ, et al. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on grading of prostatic carcinoma. Am J Surg Pathol. 2020; 44(8): e87-e99. https://doi.org/10.1097/PAS.0000000000001497
- 7Jain S, Loblaw A, Vesprini D, et al. Gleason upgrading with time in a large prostate cancer active surveillance cohort. J Urol. 2015; 194(1): 79-84. https://doi.org/10.1016/j.juro.2015.01.102
- 8Epstein JI, Amin MB, Fine SW, et al. The 2019 Genitourinary Pathology Society (GUPS) white paper on contemporary grading of prostate cancer. Arch Pathol Lab Med. 2021; 145(4): 461-493. https://doi.org/10.5858/arpa.2020-0015-RA
- 9Littrup PJ, Williams CR, Egglin TK, Kane RA. Determination of prostate volume with transrectal US for cancer screening. Part II. Accuracy of in vitro and in vivo techniques. Radiology. 1991; 179(1): 49-53. https://doi.org/10.1148/radiology.179.1.2006303
- 10Habes M, Bahr J, Schiller T, et al. New technique for prostate volume assessment. World J Urol. 2014; 32: 1559-1564.
- 11Eri LM, Thomassen H, Brennhovd B, Håheim LL. Accuracy and repeatability of prostate volume measurements by transrectal ultrasound. Prostate Cancer Prostatic Dis. 2002; 5: 273-278.
- 12Hong MK, Yao HH, Rzetelski-West K, et al. Prostate weight is the preferred measure of prostate size in radical prostatectomy cohorts. BJU Internat. 2012; 109(Suppl 3): 57-63.
- 13Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021; 79(2): 243-262. https://doi.org/10.1016/j.eururo.2020.09.042
- 14Aprikian S, Luz M, Brimo F, et al. Improving ultrasound-based prostate volume estimation. BMC Urol. 2019; 19(1): 68. https://doi.org/10.1186/s12894-019-0492-2
- 15Gündoğdu E, Emekli E. Evaluation of prostate volume in mpMRI: comparison of the recommendations of PI-RADS v2 and PI-RADS v2.1. Diagn Interv Radiol. 2021; 27(1): 15-19. https://doi.org/10.5152/dir.2020.20023
- 16Giganti F, Stavrinides V, Stabile A, et al. Prostate cancer measurements on serial MRI during active surveillance: it's time to be PRECISE. Br J Radiol. 2020; 93(1116):20200819. https://doi.org/10.1259/bjr.20200819
- 17Wasserman NF, Niendorf E, Spilseth B. Measurement of prostate volume with MRI (a guide for the perplexed): biproximate method with analysis of precision and accuracy. Sci Rep. 2020; 10(1): 575. Published 2020 Jan 17. https://doi.org/10.1038/s41598-019-57046-x
- 18Numao N, Kawakami S, Sakura M, et al. Characteristics and clinical significance of prostate cancers missed by initial transrectal 12-core biopsy. BJU Int. 2012; 109: 665-671.
- 19Komai Y, Numao N, Yoshida S, et al. High diagnostic ability of multiparametric magnetic resonance imaging to detect anterior prostate cancer missed by transrectal 12-core biopsy. J Urol. 2013; 190(3): 867-873. https://doi.org/10.1016/j.juro.2013.03.078
- 20Bott SR, Young MP, Kellett MJ, Parkinson MC. Contributors to the UCL Hospitals' Trust Radical Prostatectomy Database. Anterior prostate cancer: is it more difficult to diagnose? BJU Int. 2002; 89(9): 886-889. https://doi.org/10.1046/j.1464-410x.2002.02796.x
- 21Koppie TM, Bianco FJ, Jr., Kuroiwa K, et al. The clinical features of anterior prostate cancers. BJU Int. 2006; 98(6): 1167-1171. https://doi.org/10.1111/j.1464-410X.2006.06578.x
- 22Mai KT, Moazin M, Morash C, Collins JP. Transitional zone and anterior peripheral zone of the prostate. A correlation of small-volume cancer in the biopsy cores and high psa with positive anterior margins in radical prostatectomy specimens. Urol Int. 2001; 66(4): 191-196. https://doi.org/10.1159/000056613
- 23Delongchamps NB, Rouanne M, Flam T, et al. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging. BJU Int. 2011; 107(9): 1411-1418. https://doi.org/10.1111/j.1464-410X.2010.09808.x
- 24Tosoian JJ, Mamawala M, Epstein JI, et al. Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort. Eur Urol. 2020; 77(6): 675-682. https://doi.org/10.1016/j.eururo.2019.12.017
- 25Hadjipavlou M, Promponas J, Madaan S. Active surveillance for low-risk prostate cancer. J Clin Urol. 2015; 8(6): 420-428. https://doi.org/10.1177/2051415815592816
